Showing results (331-340 of 587) with videos related to
Sort By:
Pageof 59
European Journal of Cancer (Oxford, England : 1990)|May 22, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamicsLaura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2020
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung CancerSandra Ortiz-Cuaran, Laura Mezquita, Aurélie Swalduz, et al.Clinical Lung Cancer|February 4, 2018
Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Paul Baas, Fabrice Barlesi, et al.Investigational New Drugs|April 5, 2020
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancerNobuyuki Yamamoto, Hidetoshi Hayashi, David Planchard, et al.Lung Cancer (Amsterdam, Netherlands)|September 7, 2019
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, et al.Molecular Cell|November 29, 2007
Nonapoptotic role for Apaf-1 in the DNA damage checkpointYael Zermati, Shahul Mouhamad, Lilli Stergiou, et al.Therapeutic Advances in Medical Oncology|February 17, 2022
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLCFilippo G Dall'Olio, Claudia Parisi, Laura Marcolin, et al.Expert Review of Anticancer Therapy|July 11, 2022
Immunosenescence, inflammaging, and cancer immunotherapy efficacyJulieta E Rodriguez, Marie Naigeon, Vincent Goldschmidt, et al.Lung Cancer (Amsterdam, Netherlands)|February 2, 2024
International reproducibility study of thymic epithelial tumors staging: pT stage is an issue. proposals for improvement. A RYTHMIC/ITMIG studyThierry J Molina, Anja C Roden, Malgorzata Szolkowska, et al.Journal for Immunotherapy of Cancer|February 8, 2022
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockersBoris Duchemann, Marie Naigeon, Edouard Auclin, et al.Pageof 59